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Bloom’s syndrome (BS) is a genomic instability disorder characterized by cancer susceptibility. The protein
defective in BS, BLM, belongs to the RecQ family of DNA helicases. In this study, we found that BLM interacts
with hp150, the largest subunit of chromatin assembly factor 1 (CAF-1), in vitro and in vivo. Colocalization of
a proportion of the cellular complement of these two proteins is found at specific nuclear foci coinciding with
sites of DNA synthesis in the S phase. This colocalization increases in the presence of agents that damage DNA
or inhibit DNA replication. In support of a functional interaction between BLM and CAF-1, we show that BLM
inhibits CAF-1-mediated chromatin assembly during DNA repair in vitro. Although CAF-1 activity is not
altered in BLM-deficient cells, the absence of BLM does impair the ability of CAF-1 to be mobilized within the
nucleus in response to hydroxyurea treatment. Our results provide the first link between BLM and chromatin
assembly coupled to DNA repair and suggest that BLM and CAF-1 function in a coordinated way to promote
survival in response to DNA damage and/or replication blockade.
Bloom’s syndrome (BS) is a rare recessive genetic disorder
associated with cancer predisposition, immunodeficiency, pro-
portional dwarfism, and a sunlight-induced facial erythema
(16). Cells from BS patients display genomic instability, includ-
ing an excessive number of locus-specific mutations as well as
a high frequency of microscopically visible chromatid gaps,
rearrangements, breaks, and sister chromatid exchanges (40).
BS cells are not defective in the known DNA repair pathways
(14, 26, 38) but show a retarded rate of nascent DNA chain
elongation (18) and accumulate abnormal replication interme-
diates (29). The gene mutated in BS encodes a DNA helicase
(BLM) belonging to the RecQ family (12). Recombinant BLM
exhibits ATP-dependent 3-5 DNA helicase activity (22). Im-
munolocalization studies have shown that BLM is found
mainly in the nucleus at discrete foci (shown to coincide with
promyelocytic leukemia protein (PML) bodies) (21, 35) and in
nucleoli during S phase (55).
Recently, much attention has been paid to the characteriza-
tion of proteins that associate with the RecQ family of DNA
helicases in order to understand their exact roles in the main-
tenance of genome stability in human cells (19, 34). BLM has
been reported to interact with several proteins, including rep-
lication protein A (RPA), a DNA binding protein that plays
essential roles during DNA replication, repair, and recombi-
nation (8); topoisomerase III, a protein that, together with
BLM, can resolve intermediates that arise during homologous
recombinational repair (53, 54); BRCA1, a protein required
for efficient homologous recombination and which acts as a
signal processor for DNA damage responses (50); RAD51 and
RAD51L3, proteins required for DNA strand invasion and
exchange during homologous recombination (6, 7, 52); p53, a
tumor suppressor implicated in S-phase processes, DNA re-
pair, and homologous recombination (11, 41, 49); TRF2, a
telomere binding protein (36, 44); WRN, Werner syndrome
protein, another member of the RecQ helicase family (48);
ATM, one of the essential transducers of DNA damage check-
point responses (5); MLH1 and MSH6, proteins involved in
mismatch repair and recombination (26, 37, 38); and five Fan-
coni anemia proteins: FANCA, FANCG, FANCC, FANCE,
and FANCF, a multiprotein complex suggested to function in
a DNA damage response pathway (31). The phenotypes ex-
hibited by BS cells, as well as the proteins that can associate
with BLM protein, imply that BLM may be involved in DNA
recombination and repair processes linked to DNA replication
and in telomere maintenance. There are several lines of evi-
dence to show the importance of BLM during DNA replica-
tion. First, in Xenopus egg extracts, depletion of the Xenopus
BLM homolog (xBLM) leads to an inhibition of DNA repli-
cation that can be rescued by addition of recombinant xBLM
(27). Second, BLM/ cells possess replication defects that
include the accumulation of abnormal replication fork inter-
mediates, retarded replication fork progression, and the de-
layed maturation of Okazaki fragments (10). Third, BLM is
localized to replication foci, particularly during late S phase
(51). However, it remains unclear whether the involvement of
BLM in DNA replication is direct or is a secondary effect of
lacking efficient repair of stalled replication forks. It is there-
fore of considerable interest to study the mechanism of how
BLM influences DNA synthesis.
In this paper, we report that BLM physically and function-
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ally associates with hp150, the largest subunit of chromatin
assembly factor 1 (CAF-1). CAF-1 is a three-subunit complex
that promotes the incorporation of histones H3 and H4 into
newly synthesized DNA during replication (47) or during nu-
cleotide excision repair (15). Moreover, we show that BLM
and hp150 colocalize to sites of DNA synthesis when cells are
exposed to DNA replication inhibitors or DNA-damaging
agents. In pursuit of a biological function of the BLM-hp150
interaction, we found that BLM specifically attenuates CAF-
1-mediated chromatin assembly during DNA repair in vitro.
Furthermore, we show that in BLM/ cells, CAF-1 activity is
not altered but that the absence of BLM affects the localization
of CAF-1 following hydroxyurea (HU) treatment. Collectively,
our data indicate that BLM and CAF-1 may function together
in vivo during DNA metabolic processes and provide a novel
insight into the role of BLM and CAF-1 in the maintenance of
genome stability.
MATERIALS AND METHODS
Constructs. Construction of part of the BLM deletion mutant series (see Fig.
2) has been described previously (38). PCR products of BLM131–333 and
BLM782–952 from plasmid pJK1 (22) were cloned into the pBTM116 vector. The
presence of the correct clones was verified by sequencing and by checking
expression in yeast cells by Western blotting. hp150 and its deletion mutants were
cloned into pBTM116 and pACT2 vectors for yeast two-hybrid (YTH) testing
and into the pCITE4 vector (Novagen) for in vitro transcription-translation
analyses. Precise details of sequences and construction schemes are available on
request.
Yeast two-hybrid (YTH) assay. The screening of an activation domain (AD)
cDNA library generated from human peripheral blood mRNA using the C-
terminal 647 amino acids of BLM as a bait was performed as described previ-
ously (38). Standard yeast transformation and interaction tests were used to map
the interaction domains for BLM and hp150. Yeast strain L40 (MATa trp1 leu2
his3 LYS2::lexA-HIS3 URA3::lexA-lacZ) was used.
In vitro binding assay. Different amounts (1.25, 2.5, and 5 pmol) of purified
recombinant BLM, which was diluted in protein storage buffer (50 mM Tris-HCl
[pH 7.5], 100 mM NaCl, 1 mM EDTA, 1 mM -mercaptoethanol, 25% [vol/vol]
glycerol) were dotted on a nitrocellulose membrane (MSI NitroBind); bovine
serum albumin (BSA) and UvrD were dotted as control proteins. After being air
dried for 15 min, the membrane was blocked for 2 h at room temperature in
Tris-buffered saline (TBS) supplemented with 2.5% (wt/vol) milk and 0.05%
(vol/vol) Tween 20 and then incubated for 3 h at 4°C, with different proteins that
were 35S labeled using the TNT quick transcription-translation system (Pro-
mega), in 1 ml of TBS with 0.1% (wt/vol) BSA and 0.05% (vol/vol) Tween 20.
Aliquots (20 l) of the in vitro transcription-translation reaction mixture were
used for each incubation. After extensive washing with TBS containing 0.05%
Tween 20, the membranes were dried and exposed to a PhosphorImager (Mo-
lecular Dynamics).
Co-IP. Portions (200 g) of nuclear extract from BJAB cells, as well as
untreated or HU-treated HeLa cells, were incubated with either 8 l of anti-
hp150 antibody (MAb1) (42) or 2 g of control immunoglobulin G (IgG) in
immunoprecipitation (IP) buffer (20 mM HEPES [pH 7.5], 120 mM KCl, 5 mM
MgCl2, 0.1% [vol/vol] NP-40, protease inhibitors) at 4°C for 3 h in a total
reaction volume of 200 l. Then 40 l of IP buffer-equilibrated protein G-
Sepharose beads (Amersham Pharmacia Biotech) was added, and the mixture
was incubated for 3 h at 4°C. The beads were washed five times with wash buffer
(IP buffer supplemented with an additional 20 mM KCl) before the protein
complexes bound to the beads were eluted and split into two portions for sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). A 10-g por-
tion of nuclear extract was used as the input control. Western blot analysis with
an anti-BLM antibody, IHIC33 (53), and an anti-hp150 polyclonal antibody (gifts
from Genevie`ve Almouzni) were used to detect proteins immunoprecipitated by
MAb1. Enhanced chemiluminescence was performed as specified by the manu-
facturer (Amersham Pharmacia Biotech). Two other anti-hp150 antibodies were
also used in the IP assays: MAb anti-CAF-1 p150 (Novus Biologicals) and Ab-3
(Oncogene Research Products). C-18 (anti-BLM; Santa Cruz) was used for the
reverse IP in the above-described IP buffer containing 100 to 150 mM KCl.
Nuclear extracts from BS cells were used as a negative control for the C-18
reverse IP.
Cellular fractionation. Exponentially growing HeLa cells, BS cells
(GM08505), and BS cells containing the BLM cDNA (PSNF5 cells) (53) were
harvested in phosphate-buffered saline (PBS) and washed twice with buffer A (10
mM HEPES [pH 7.9], 1.5 mM MgCl2, 10 mM KCl, 1 mM phenylmethylsulfonyl
fluoride [PMSF], 5 mM dithiothreitol [DTT], protease inhibitors) before the
pellet was resuspended in 3 volumes of buffer A (buffer A containing an
additional 0.1% NP-40). After incubation for 5 min, the cells were centrifuged
and the pellet was resuspended in 3 volumes of buffer C (20 mM HEPES [pH
7.9], 420 mM NaCl, 1.5 mM MgCl2, 25% [vol/vol] glycerol, 1 mM PMSF, 5 mM
DTT, other proteinase inhibitors) and incubated on ice for 15 min. Finally, after
the mixture was pelleted, the supernatant was taken as the soluble fraction of
nuclear proteins (the concentration of NaCl was adjusted to 120 mM with buffer
D, which contains 20 mM HEPES [pH 7.9], 1 mM PMSF, 5 mM DTT, and
proteinase inhibitors) and the pellet was either subjected to ultrasonication to
dissolve the insoluble fraction of nuclear proteins in SDS sample buffer or
digested with DNase I in DIG buffer (50 mM NaCl, 10 mM Tris [pH 6.8], 3 mM
MgCl2, 1 mM EGTA, 0.5% Triton, 100 g of DNase I per ml, 50 g of RNase
A per ml, 1.2 mM PMSF) for 30 min at room temperature before the chromatin
fraction was separated from the nuclear matrix fraction.
Cell synchronization and immunofluorescence microscopy. HeLa cells, BS
cells, and PSNF5 cells (BS cells containing the BLM cDNA [BLM/  pBLM])
were grown on chamber slides (Lab-Tek) to up to 50% confluence before being
subjected to synchronization or treatment with variant DNA-damaging agents.
For a G1/S block, 5 mM thymidine and 2 g of aphidicolin per ml were added to
the cells for 28 and 24 h, respectively; for S-phase synchronization, 2 mM HU was
used for 24 h; for a G2/M block, 1 g of nocodazole per ml was incubated with
the cells for 24 h. Synchronized cells or cells taken 20 h after treatment with
N-methyl-N-nitro-N-nitrosoguanidine (MNNG) or 4 to 18 h after UV treatment
were permeabilized with 0.5% (vol/vol) Triton in PBSS (PBS supplemented with
5 mM MgCl2) plus 5 mM PMSF for 5 min at room temperature before being
fixed in 2% paraformaldehyde for 20 min. After 20 min of further treatment with
0.5% (vol/vol) Triton, and following washing with PBSST (PBSS with 0.1%
[vol/vol] Tween 20), the slides were blocked for 20 min in PBSST plus 5%
(wt/vol) BSA before being incubated with the primary antibodies anti-BLM
(1:200) (32), anti-RPA (1:50; Ab-1 [Oncogene Research Products]), anti-
BRCA1 (1:100; Ab-1 [Oncogene Research Products]), anti-hp150 polyclonal
antibody (1:2,000), and anti-hp150 MAb1 (1:100; Ab-3 [Oncogene research
products]) for 2 h at room temperature. To visualize the primary antibodies,
Cy3-conjugated goat anti-rabbit IgG (1:200; Jackson ImmunoResearch) and
5-(4,6-dichlorotriazin-2-yl)aminofluorescein (DTAF)-coupled goat anti-mouse
IgG (1:100; ANAWA) or fluorescein isothiocyanate-coupled goat anti-mouse
IgG (1:100; Jackson ImmunoResearch) were used, and 1 g of 4,6-diamidino-
2-phenylindole (DAPI) per ml was added to stain the DNA. The stained cells
were mounted in Vectashield (Vector Laboratories) and observed under a Leica
TCS 4D confocal microscope. Imaris software was used to process the images.
Chromatin assembly assay. An in vitro chromatin assembly assay with a
human cell-free system was utilized to analyze the effect of recombinant BLM on
DNA repair-coupled chromatin assembly (15). Briefly, UV (500 J/m2)-irradiated
circular pBluescript plasmid DNA was incubated for 3 h at 37°C with cytosolic
extract derived from HeLa cells (30) supplemented with purified recombinant
CAF-1 complex or with nuclear extract from either HeLa or BS cells (47) in the
presence or absence of recombinant native BLM or BLM preincubated with
anti-BLM antibody (32). The extent of supercoiling was examined by agarose gel
electrophoresis followed by drying of the gel and exposure to X-ray film. Incor-
poration of [-32P]dCTP indicates newly synthesized DNA after nucleotide ex-
cision repair.
RESULTS
BLM and hp150 interact in vitro and in vivo. To identify
proteins that interact with BLM, we screened an AD cDNA
library generated from human peripheral blood mRNA, using
the C-terminal 647 amino acids of BLM as a bait (38). Two
interacting clones contained amino acids 39 to 938 and 238 to
938 of hp150 fused in frame to the AD (Fig. 1A). To ascertain
the specificity of this interaction, we analyzed whether either of
the AD-hp150 fusions could interact with a nonspecific control
protein, yeast Dna2p. The resulting phenotype of the trans-
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formed yeast was His3 LacZ, indicating that hp150 of hu-
man CAF-1 does not interact with Dna2p. We conclude that
hp150 specifically binds to the C terminus of BLM in the YTH
system (Fig. 1A).
To substantiate this interaction further, we tested whether
BLM and hp150 could interact in vitro. To this end, full-length
recombinant BLM protein was immobilized on a nitrocellulose
filter, which was then incubated with in vitro-translated hp150
or its derivatives (Fig. 1C). As shown in Fig. 1B, the two
truncated forms of hp150 found in the YTH screen, as well as
the full-length hp150, interacted with BLM. Since in vitro-
translated hp150 and the two N-terminally truncated forms did
not interact with either of two control proteins, BSA and the
bacterial helicase UvrD (Fig. 1B), we conclude that the inter-
action between BLM and hp150 is specific and direct, not
requiring additional accessory proteins. This direct interaction
was also confirmed by an in vitro co-IP assay by incubating the
purified recombinant BLM with in vitro-translated hp150 and
then with the MAb against hp150 (data not shown, available on
request).
To gain insight into the BLM-hp150 interaction in vivo, we
performed co-IP experiments with nuclear extracts of human
BJAB cells, using a MAb directed against hp150 (Fig. 1D).
Endogenous BLM was effectively coprecipitated by the hp150
FIG. 1. BLM and hp150 interact both in vitro and in vivo. (A) Interaction of BLM and hp150 analyzed by the YTH assay. The left panel
illustrates the AD-hp150 constructs. The PEST, KER, and ED regions of hp150 are indicated. The right panel shows the corresponding
-galactosidase activities with either LexA-BLM(770–1417) (black bars) or LexA-Dna2 (white bars). (B) In vitro binding assay. Different amounts
(lane 1, 0 pmol; lane 2, 1.25 pmol; lane 3, 2.5 pmol; lane 4, 5 pmol) of purified recombinant BLM protein, BSA, or UvrD were dotted on a
nitrocellulose membrane and incubated with in vitro-transcribed and -translated full-length hp150, hp15039–938, and hp150238–938, respectively, as
indicated on the left. Signals were detected by autoradiography using a PhosphorImager. (C) An autoradiogram (left panel) of in vitro-transcribed
and -translated full-length hp150 (lane 1), hp15039–938 (lane 2), and hp150238–938 (lane 3) used in the in vitro binding assay. Purified recombinant
BLM protein (middle panel, lane 4) and UvrD protein (right panel, lane 5) were subjected to SDS-PAGE and stained with Coomassie blue. The
positions of molecular mass standards are also indicated (lane 6). (D) BLM was coimmunoprecipitated from BJAB human nuclear extracts with
an anti-hp150 MAb (MAb1, lane 3) but not with the control IgG (lane 2). One-tenth the amount of the same nuclear extract was used as input
control (lane 1). Reciproical co-IP is shown in lanes 4 to 7: lane 4, input; lane 5, IP with the control IgG; lane 6, IP with an anti-BLM antibody
(C-18) in 100 mM KCl salt condition; lane 7, IP with an anti-BLM antibody (C-18) in 150 mM salt condition. The known BLM-interacting protein,
topoisomerase III (TOPOIII), was also efficiently coimmunoprecipitated using the same anti-BLM antibody (lane 6). (E) Co-IP with anti-BLM
antibody (C-18) from BS cell nuclear extracts (BLM/)and BS cells containing the BLM cDNA (BLM/  pBLM). hp150 could be coimmu-
noprecipitated in the presence (lane 4) but not in the absence (lane 3) of BLM. Lanes 1 and 2 are the inputs of the two different nuclear extracts.
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antibody (Fig. 1D, lower panel, lane 3) but was not detected
when the hp150 antibody was omitted (lane 2). Similar results
were obtained with two other anti-hp150 antibodies (data not
shown). The reciprocal co-IP experiment was also carried out,
in which an anti-BLM polyclonal antibody (C-18; Santa Cruz)
was used to immunoprecipitate hp150 from HeLa nuclear ex-
tracts. As shown in Fig. 1D, hp150 could be specifically coim-
munoprecipitated with anti-BLM (middle panel, lanes 6 and 7)
but not with the control IgG antibody (lane 5). The results of
this co-IP experiment have indicated that in soluble HeLa
nuclear cell extracts, less than 10% of total hp150 is associated
with BLM (data not shown, available upon request). More-
over, in addition to hp150, anti-BLM antibody efficiently co-
precipitated topoisomerase III (Fig. 1D, bottom panel, lane
6), a protein known to interact with BLM (53). Importantly,
the anti-BLM antibody (C-18) could not immunoprecipitate
hp150 from BS (BLM/) cells (Fig. 1E, lane 3) whereas it
efficiently immunoprecipitated hp150 from BS cells containing
the BLM cDNA (BLM/  pBLM) (lane 4). We conclude
from these different protein interaction experiments that BLM
associates with hp150 of CAF-1 in yeast, in vitro, and in human
cells.
Mapping of interaction regions on BLM and hp150. To
identify the region of BLM that mediates the interaction with
hp150, we generated a series of BLM deletion mutants. These
deletion mutants were tested for interaction with the full-
length hp150 in the YTH assay (Fig. 2A). Two independent
regions in BLM were found to interact with hp150. The first
interacting region resides at the N terminus of BLM and com-
prises amino acids 131 to 333, and the second region is located
in the middle of the helicase domain and comprises amino
acids 782 to 952 of BLM (Fig. 2A). The relatively weaker
interaction of BLM amino acids 131 to 333 and BLM amino
acids 782 to 952 with hp150 compared to that of full-length
BLM could be due to ineffective folding of these two short
forms. A similar YTH approach combined with an in vitro
binding assay was used to map the BLM interaction region on
hp150 (Fig. 2B). One region of hp150, comprising amino acids
551 to 714 containing the ED domain (amino acids 564 to 641)
(24) and the dimerization domain (amino acids 642 to 678)
(39), was found to be necessary and sufficient for interaction
with BLM. Interestingly, this region is different from the region
in hp150 that interacts with proliferating-cell nuclear antigen
in vitro (33) and from the region critical for the interaction
with p60, another subunit of CAF-1 (24).
BLM and hp150 colocalize on DNA replication block or
DNA-damaging signals. Next, we analyzed whether BLM and
hp150 colocalize within the nucleus of intact human cells by
indirect immunofluorescence of exponentially growing HeLa
cells. Previous studies using HeLa cells have shown that CAF-1
is present at replication foci, since it localizes at sites of 5-bro-
modeoxyuridine incorporation (25, 45). In these cells, BLM
forms nuclear foci corresponding to PML nuclear bodies (21,
52). The observation of nuclear foci containing BLM with
PML, RPA, and 5-bromodeoxyuridine led to the suggestion
that these sites represent sites of DNA synthesis and repair (6).
In untreated HeLa cells, we detected some nuclear foci that
were enriched in both BLM and hp150. Under these condi-
tions, only 7% of the cells contained a mean of 1.8 colocalizing
BLM and hp150 foci per nucleus (Fig. 3A and Table 1). This
observation suggested that the two proteins might associate at
sites of endogenous damage during the replication process. We
therefore asked whether the number of colocalizing BLM-
hp150 foci increased in response to treatment of the cells with
HU. Indeed, following a 20-h HU treatment, the proportion of
cells containing BLM-hp150 colocalizing nuclear foci in-
creased significantly, such that 40% of the population con-
tained a mean of 7.6 colocalizing foci per nucleus (Fig. 3A;
Table 1). We then tested whether other DNA-damaging agents
resulted in increased BLM-hp150 colocalization. At 4 h after
treatment of HeLa cells with UV light (50 J/m2), 25% of the
cells contained a mean of 4.2 BLM-hp150 colocalizing foci per
FIG. 2. Interaction region mapping of BLM and hp150. (A) Two
hp150-interacting regions (IR1 and IR2) were identified on BLM.
Full-length BLM protein and its deletion mutants used in the YTH
assay are shown in the upper panel. The numbers on the left represent
the starting and ending amino acids of the protein fragments. In the
column on the right, headed YTH test with p150,  indicates a strong
interaction, / indicates a weak interaction, and  indicates no
interaction in the YTH assay (as judged by the intensity of blue color
in the test). The lower panel depicts the helicase domain and the
nuclear localization signals (NLS) in the full-length BLM (on the same
scale as in the upper panel), as well as the two minimal regions in BLM
(IR1 and IR2) that mediate the interaction with hp150. (B) The BLM-
interacting region on hp150 is located between amino acids 551 and
714. In the upper panel, the sequence boundaries of the deletion
mutants tested in the YTH and in vitro binding assays (IVB) are shown
with the corresponding amino acid positions indicated on the left. The
results are summarized on the right. The lower panel depicts the
domain diagram of hp150 showing the PEST, KER, and ED domains
to scale with the upper panel. The region (IR) of hp150 that is nec-
essary and sufficient for the interaction with BLM is shown.
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nucleus. In addition, after exposure of HeLa cells to MNNG
for 20 h, 36% of the HeLa cells contained a mean of 6.9
BLM-hp150 colocalizing foci (Fig. 3A; Table 1), demonstrating
that this significant increase in BLM-hp150 colocalization is
irrespective of the type of DNA damage present.
To examine the BLM-hp150 interaction on inhibition of
DNA replication, we treated HeLa cells with HU, an agent
that inhibits ribonucleotide reductase and thereby halts DNA
replication fork progression, and coimmunoprecipitated pro-
teins from soluble nuclear extracts with an anti-hp150 MAb.
This treatment did not appear to dramatically change the
amount of the BLM-hp150 complex (data not shown). Similar
results were observed following treatment of HeLa cells with
the alkylating agent MNNG (data not shown). Next, we exam-
ined if the amount of BLM and/or hp150 increases in the
fraction of insoluble nuclear proteins after HU treatment. To
that end, HeLa cell nuclear proteins were resolved into soluble
(Fig. 3B, lanes 1 and 2) and insoluble (lanes 3 and 4) fractions,
which were subjected to SDS-PAGE followed by Western blot-
ting for BLM (upper panel), hp150 (middle panel), or SP1
(lower panel), the last of which was used as a loading control
(28). Interestingly, the amount of both BLM and hp150 in-
creased, although to different extents, in the insoluble (lane 4),
but not the soluble (lane 2) fraction of nuclear proteins after
HU treatment of HeLa cells. To determine the fraction of
insoluble nuclear proteins in which BLM and CAF1-hp150
were associated, we separated chromatin from the nuclear
matrix fraction. As shown in Fig. 3C, most of the functional
BLM and hp150 were found to be associated with the nuclear
matrix fraction of the insoluble nuclear structure, as judged by
the presence of the nuclear matrix marker protein lamin B. To
define further the sites in the nucleus where BLM and hp150
colocalize, additional immunofluorescence experiments were
performed with antibodies to proteins involved in replication,
repair, and recombination. RPA is a nuclear protein that in-
teracts with BLM (8) and localizes at sites of DNA replication
in nuclei of different cell types (3, 9). BRCA1, another BLM-
interacting protein (50), is required for efficient homologous
recombination and serves as a signal processor for DNA dam-
age responses (46). We found that following treatment with
HU, UV, or MNNG, both BLM and hp150 colocalized with
BRCA1 in discrete nuclear foci (Fig. 3D and data not shown).
Similarly, both BLM and hp150 co-localized with RPA in HU-,
FIG. 3. BLM and hp150 colocalize within distinct nuclear foci in
response to DNA-damaging signals. (A) Indirect immunofluorescence
of BLM (red) and hp150 (green) in untreated and HU-, MNNG-, and
UV-treated HeLa cells. Representative pictures are shown for a por-
tion of cells analyzed. For details, see Table 1. In the merged image,
colocalization is seen as yellow. The panel labeled DNA indicates the
position of the nucleus, as judged by DAPI staining. Bars, 10 m.
(B) The amount of BLM and hp150 increases after HU treatment in
the insoluble fraction of nuclear proteins. Untreated (lanes 1 and 3)
and HU-treated (lanes 2 and 4) HeLa nuclear proteins were resolved
into soluble (lanes 1 and 2) and insoluble (lanes 3 and 4) fractions, and
these were subjected to SDS-PAGE followed by Western blotting for
BLM (top panel), hp150 (middle panel), and SP1 (bottom panel [load-
ing control]). (C) The increased amount of BLM and hp150 is mainly
associated with the nuclear matrix. After DNase 1 digestion, the in-
soluble nuclear fraction was separated into two fractions: chromatin
(lanes 1 and 2) and nuclear matrix (lanes 3 and 4). Lanes 1 and 3
contain untreated HeLa cells; lanes 2 and 4 contain HU-treated HeLa
cells. Lamin B is shown as a fractionation and loading control.
(D) BLM and hp150 colocalize with BRCA1 after HU treatment of
HeLa cells. Red foci represent either BLM or hp150, and green foci
reveal BRCA1 staining. DNA is revealed by DAPI staining. Bars, 10
m. (E) BLM and hp150 colocalize with RPA after HU treatment of
HeLa cells. Red represents either BLM or hp150, as indicated, and
green indicates RPA protein. DNA indicates the position of nucleus.
Bars, 10 m. See Results and Discussion for details.
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UV-, or MNNG-treated HeLa cells (Fig. 3E and data not
shown). Taken together, these immunofluorescence data sug-
gest that after treatment of cells with DNA-damaging agents or
in response to endogenous damage, a proportion of BLM and
hp150 colocalize at sites of ongoing DNA synthesis and repair.
BLM-hp150 colocalization is cell cycle dependent. Since the
subcellular localization patterns for BLM and CAF-1 are not
identical during a normal, unperturbed cell cycle (25, 55), we
set out to determine the stage of the cell cycle at which BLM
and hp150 colocalize to the greatest extent. For this purpose,
we synchronized HeLa cells in the G1/S, early S, and G2/M
phases (Fig. 4A) and immunostained the cells with anti-BLM
and anti-hp150 antibodies. Figure 4B and C show the pattern
of BLM-hp150 colocalization in G1/S- and S-phase cells, re-
spectively. As before, only a portion of cells exhibited BLM-
hp150 colocalizing foci: only 3% of the G1/S phase cells con-
tained BLM-hp150 colocalizing foci, while 38% of the S-phase
cells displayed BLM-hp150 colocalization. During the G2/M
stage, no cells showed any BLM-hp150 colocalization (data not
shown). This reveals that colocalization between BLM and
hp150 occurs most frequently during the S phase, where the
majority of DNA replication and repair events are occurring.
BLM inhibits CAF-1-mediated chromatin assembly coupled
to DNA repair. Next, we investigated the functional conse-
quences of the interaction between BLM and hp150 by ana-
lyzing whether BLM affects the activity of hp150 in terms of its
critical role in chromatin assembly. To address this, we used
the in vitro chromatin assembly assay coupled to repair of
UV-damaged DNA. This assay takes advantage of simulta-
neous analysis of DNA repair and chromatin assembly pro-
cesses on the same damaged circular DNA template (15).
HeLa cytosolic extracts complemented by recombinant CAF-1
efficiently mediated DNA repair-linked chromatin assembly, as
indicated by the appearance of radioactively labeled form I
DNA molecules corresponding to supercoiled, repaired DNA
(Fig. 5A, lane 2). In this reaction, chromatin assembly that
occurs independently of DNA synthesis or repair is very inef-
ficient and appears to be CAF-1 independent (data not
shown). Addition of purified BLM alone, in the absence of
recombinant CAF-1, did not result in the formation of super-
coiled molecules (Fig. 5B, lane 1). However, preincubation of
CAF-1 complex with recombinant BLM led to a significant
decrease in the amount of supercoiled product (Fig. 5A, lanes
3 and 4), indicating that BLM acted as an inhibitor of CAF-
1-mediated chromatin assembly coupled to DNA repair. When
recombinant BLM was preincubated with anti-BLM antibody
before addition of the mixture to the chromatin assembly re-
action mix, the BLM no longer inhibited CAF-1-dependent
DNA repair-coupled chromatin assembly (Fig. 5A, lanes 5 and
6). This is most probably due to an inability of the antibody-
complexed BLM to interact productively with hp150. No effect
on CAF-1-mediated chromatin assembly was observed when
anti-BLM antibody alone was added to the reaction mix (lane
7). Importantly, chloroquine gel analysis demonstrated that
there was no difference in the topology of the DNA repaired by
the cytosolic extracts in the presence or absence of BLM (data
not shown), thus excluding the possibility that BLM-mediated
inhibition of chromatin assembly is due to the effect of BLM on
topoisomerases in our system.
Next, we asked whether the inhibitory effect of BLM on
CAF-1-mediated chromatin assembly could be relieved by the
addition of an excess of purified CAF-1 holoenzyme complex.
Figure 5B (lane 4) shows that a significant and CAF-1 concen-
tration-dependent relief of BLM-mediated inhibition of chro-
matin assembly was detected on the addition of the CAF-1
holoenzyme complex. Most importantly, this inhibition of
CAF-1-mediated chromatin assembly is specific for BLM,
since the bacterial helicase UvrD, which does not interact with
hp150 (Fig. 1B), showed no inhibitory effect on CAF-1-medi-
ated chromatin assembly (Fig. 5C, lane 3). Collectively, these
results argue for a role of BLM in inhibiting CAF-1-dependent
chromatin assembly coupled to DNA repair through a direct
protein-protein interaction.
We also tested how p150 affects BLM helicase activity. Al-
though hp150 inhibited BLM-catalyzed DNA unwinding, this
appeared to be a nonspecific effect, probably mediated via the
binding of hp150 to the DNA substrate, because hp150 also
inhibited UvrD (data not shown, available on request).
BLM is required for an optimal CAF-1 response to HU. To
further study the in vivo functional relationship between BLM
and CAF-1, we examined CAF-1 function in BLM-deficient
cells. To determine whether CAF-1-mediated chromatin as-
sembly is affected in BS cells, we prepared nuclear extracts
from BS cells and compared them with the nuclear extracts
from wild-type (HeLa) cells for their ability to mediate chro-
matin assembly. The presence and absence of BLM in these
cell lines was controlled by Western blotting (Fig. 6C). As
shown in Fig. 6A, the endogenous CAF-1 activity was not
obviously altered in BS cells (lane 2) compared with the CAF-1
activity from wild-type cells (lane 1).
Next, we investigated whether CAF-1 forms normal nuclear
foci in untreated or HU-treated BS cells. Immunofluorescence
analysis of the subcellular localization of hp150 indicated that
CAF-1 formed normal nuclear foci in both untreated and HU-
TABLE 1. Proportion of cells containing foci and number of nuclear foci containing both BLM and hp150 in HeLa cellsa
Treatment
% of cells containing: Mean no. of foci/cell (range) % of cells containing BLM andCAF-1 colocalizing foci
Mean no.
of BLM
and CAF-1
colocalizing
foci/cell
BLM
foci
CAF-1
foci BLM foci CAF-1 foci
0
foci
1–5
foci
5
foci
None 36 9 4.2 (0–27) 3.1 (0–29) 93 6 1 1.8
HU (5 mM) 85 68 22.2 (0–51) 29.6 (0–54) 60 32 8 7.6
MNNG (5 M) 94 57 26.8 (0–66) 23.3 (0–49) 64 29 7 6.9
UV 45 37 6.8 (0–30) 6.3 (0–32) 75 23 2 4.2
a In each case, 150 cells were scored.
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treated BS cells (Fig. 6B). In untreated BS cells, the percent-
age of cells containing CAF-1 foci (6.7%) did not significantly
differ compared with that in untreated PSNF5 cells [BS cells
containing the BLM cDNA (BLM/  pBLM)] (7.1%), sug-
gesting that BLM is not required for recruitment of CAF-1 to
nuclear foci. In HU-treated BS cells, the percentage of cells
containing CAF-1 foci (18%) increased compared with that in
untreated BS cells (6.7%). In PSNF5 cells which contain the
BLM cDNA, the percentage of cells containing CAF-1 foci
(43%) also increased in the presence of HU compared to that
FIG. 4. BLM-hp150 colocalization is cell cycle dependent. (A) Flu-
orescence-activated cell sorter analysis of HeLa cells, which were ei-
ther unsynchronized (control) or synchronized at different cell cycle
stages: G1/S, early S, and G2/M (see Materials and Methods).
(B) HeLa cells blocked at the G1/S phase boundary (see Materials and
Methods) were immunostained for BLM and hp150. DAPI staining
was for nuclear DNA. Bar, 10 m. (C) Colocalization of BLM and
hp150 in S-phase HeLa cells (see Materials and Methods and the
Results section for more information). Bar, 10 m.
FIG. 5. BLM inhibits CAF-1-mediated chromatin assembly cou-
pled to DNA repair. (A) Addition of BLM inhibits CAF-1 activity.
Each lane contains 75 ng of UV-irradiated circular pBluescript plas-
mid DNA, as indicated above the figure. Purified CAF-1 complex is
present in lanes 2 to 7 but not in lane 1 which serves as a negative
control. The concentration of recombinant BLM was 10 nM in lane 3
and 25 nM in lanes 4 to 6. In lanes 5 and 6, BLM protein was incubated
with 1 l of anti-BLM antibody before being added to the chromatin
assembly reaction mix. Lane 7 is a control of anti-BLM antibody. The
positions of the relaxed/nicked (Ir, II) and supercoiled (I) DNA are
indicated on the right. (B) An excess of CAF-1 holoenzyme complex
restores BLM-mediated inhibition of chromatin assembly in vitro. A
75-ng portion of UV-irradiated plasmid DNA was used in each lane;
25 nM BLM was added in lanes 1, 3 and 4, but not in lane 2. CAF-1 was
present only in lanes 3 and 4, at 0.5 and 4 nM, respectively. The
positions of the relaxed/nicked (Ir, II) and supercoiled (I) DNA are
indicated on the right. (C) Inhibition of CAF-1 activity is BLM specific.
Bacterial helicase UvrD does not inhibit CAF-1-mediated chromatin
assembly coupled to DNA repair (lane 3). Lanes 1 and 2 are negative
and positive controls, respectively.
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in untreated cells (7.1%). However, this increase in the per-
centage of CAF-1-foci containing cells observed in HU treated
PSNF5 cells was greater than that seen in BS cells alone. This
result suggests that BLM is required for an optimal CAF-1
response to HU and is consistent with the cellular fractionation
experiment showing an increase in the amount of hp150 asso-
ciated with nuclear matrix in PSNF5 cells containing the BLM
cDNA compared to that in BS cells alone (Fig. 6D).
DISCUSSION
To maintain genome stability, both genetic and epigenetic
information has to be correctly inherited from mother cells
after cell division. BLM and other members of the RecQ he-
licase family play a crucial role in maintaining genome stability
through their ability to suppress inappropriate recombination
(4, 19). Consistent with this notion, BS cells show increased
rates of homologous recombination and the aberrant resolu-
tion of this event (14, 41). However, the action of BLM per se
does not suffice to preserve genome integrity. The newly syn-
thesized DNA, either newly-replicated or repaired, has to be
assembled into chromatin to make sure that the genome is also
epigenetically stable, and CAF-1 plays a critical role in this
process (17). Recent results clearly showed not only that
CAF-1 is directly involved in DNA replication (20) but also
that it ensures the maintenance of epigenetic information by
acting at the sites of DNA repair (17). The results presented in
this paper suggest a cross talk between the genetic and epige-
netic pathways in the maintenance of genome stability. In
particular, we have shown that BLM physically and function-
ally associates with hp150, the largest subunit of CAF-1. The
results of our interaction region mapping experiments indicate
that BLM interacts with hp150 via two separate sites on BLM,
the first located near the N terminus of BLM (amino acids 131
to 333) and the second located in the middle of the helicase
domain (amino acids 782 to 952) of BLM. Furthermore, we
have shown that one region of hp150 (amino acids 551 to 714)
containing the ED domain and the dimerization domain is
necessary and sufficient for interaction with BLM.
Our results show that the proportion of detergent-resistant
BLM and CAF-1 foci that colocalize in the nucleus increases
after replication fork inhibition and treatment of cells with
DNA-damaging agents. Together with the nuclear fraction-
ation experiments, this suggests that the function of the BLM-
hp150 interaction is associated with the matrix fraction of nu-
clear proteins. The increase in the number of foci containing
FIG. 6. BLM is required for a proper CAF-1 response to HU treatment. (A) Chromatin assembly assay using either the HeLa cell nuclear
extracts (lane 1) or nuclear extracts prepared from BLM/ cells (lane 2). The amounts of nuclear extract added to the reaction mixes are
approximately equal, as shown at the bottom by Western blotting with an anti-hp150 antibody. (B) Immunostaining of hp150 revealed normal
CAF-1 foci in morphology in both untreated and HU-treated BS cells. Bars, 10 m. (C) Western blot showing that no BLM is detected in BS
cells (lanes 2 and 3). Lane 1 is the positive control. Lanes 4 and 5 show that BLM is present in PSNF5 cells corrected with the full-length BLM
cDNA. (D) Western blot showing that in BS cells, HU treatment did not result in as great an increase of nuclear matrix-associated hp150 (lanes
1 and 2) compared with PSNF5 cells corrected with the BLM cDNA (lanes 3 and 4). Lanes 1 and 3 contain untreated cells; lanes 2 and 4 contain
HU-treated cells. Lamin B serves as the loading control.
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both BLM and hp150 after HU treatment suggests that the
BLM-hp150 complex concentrates in the vicinity of stalled
replication forks. These replication forks probably contain
nonduplex DNA structures, which might provoke a DNA dam-
age response. In addition, BLM and hp150 are recruited to-
gether to discrete foci after DNA damage induction with
MNNG or UV light. One interpretation of these phenomena is
that in each case, the foci represent DNA repair processes that
are initiated at a replication fork. In the case of HU treatment,
as well as of UV- and MNNG-induced damage, stalled DNA
replication may also be accompanied by a recombinational
DNA damage response. The colocalization of BLM and hp150
at sites containing RPA and BRCA1 further supports the con-
tention that the BLM-hp150 complex plays a repair role during
DNA synthesis. Although the results of our indirect immuno-
fluorescence experiments show that BLM is not required for
recruitment of CAF-1 to nuclear foci, BLM seems to be
required for an optimal CAF-1 response to HU. That the
physical interaction between BLM and hp150 is of functional
significance is indicated by the inhibitory effect of BLM on
CAF-1-mediated chromatin assembly coupled to repair. This
inhibitory effect appeared specific because a control helicase,
UvrD, was unable to inhibit chromatin assembly.
Given all these observations, we propose that the BLM-
hp150 interaction is important during times when DNA syn-
thesis is perturbed in human cells. On the basis of our results,
we propose a model suggesting a functional link between BLM
and hp150 in restoring functional replication forks following
fork stalling. Progression of a replication fork might be im-
peded by DNA secondary structures such as G-quadruplexes
and DNA hairpins, thus causing the regression of the fork and
formation of a four-way junction, a structural analog of a
Holliday junction. It has been suggested previously that BLM
and other RecQ helicases process such lesions that arise at
replication forks (or are generated by the translocating fork
itself) and, in doing so, reset the fork by “reverse” branch-
migrating the four-way junction. This has the effect of prevent-
ing cleavage of the four-way junction and hence suppressing
subsequent “promiscuous” recombination (10, 19, 23, 51). A
second potential role for BLM at replication forks has been
suggested by our recent observation that BLM and topoisom-
erase III together catalyze the dissolution of a recombination
intermediate containing a double Holliday junction (54). Such
double Holliday junctions are predicted to arise during post-
replication gap filling when lesions on the lagging-strand tem-
plate are bypassed. It is known that CAF-1-dependent chro-
matin assembly occurs on newly replicated DNA (43) and that
CAF-1 is required in vitro for chromatin assembly following
DNA repair (15). CAF-1 binds directly to PCNA, a DNA
polymerase processivity factor that forms a sliding clamp
around DNA, and the CAF-1–PCNA interaction promotes
chromatin assembly (33). Although it remains unclear exactly
how BLM and CAF-1 act after damage at a replication fork,
our data suggest that the recruitment of BLM, probably not by
CAF-1, may inhibit CAF-1, and hence chromatin assembly, in
the vicinity of a stalled replication fork, perhaps to allow more
efficient lesion processing. We envisage that such inhibition
would continue until the point where normal replication struc-
tures are restored. Once the DNA lesion is bypassed and the
replication fork is restored, the CAF-1 complex can be reacti-
vated (it again assembles the newly synthesized DNA into
chromatin) and DNA replication fork progression can resume.
This sequential scheme requires a level of regulation that
may be achieved by posttranslational modification. Interest-
ingly, BLM is phosphorylated following DNA damage (1, 2,
13), and UV damage induces changes in the amount of chro-
matin-bound phosphorylated CAF-1 complex (30). It is possi-
ble that either of these phosphorylation events or some other
posttranslational modification(s) could be responsible for
modulating both physical and functional interactions between
BLM and CAF-1. The inhibitory effect of BLM on CAF-1
might also be modulated by associations with other interacting
proteins. A candidate would be PCNA, which can bind to both
CAF-1 (33) and BLM (S. L. Davies, J.-L. Li, and I. D. Hickson,
unpublished data).
While the precise biochemical relationship between BLM
and CAF-1 remains to be fully elucidated, the physical and
functional interactions documented here provide a basis to
further understand how BLM and hp150 function together to
facilitate DNA repair and/or replication.
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